Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

European Commission Approves 4-Week Nivolumab Dosing Schedule in Adjuvant Melanoma

Gina Columbus
Published: Thursday, Oct 24, 2019

Ralu Vlad, PharmD, development team lead, product design and delivery, Bristol-Myers Squibb

Ralu Vlad, PharmD

The European Commission has approved nivolumab (Opdivo) at a flat dosing schedule of either 240 mg over 30 minutes every 2 weeks, or 480 mg infused over 60 minutes every 4 weeks, for the adjuvant treatment of patients with melanoma who have involvement of lymph nodes or metastatic disease who have undergone complete resection.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication